Lake Street: AMT-130 Could Be Game-Changer For ClearPoint

uniQure N.V. (NASDAQ:QURE) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Lake Street Capital reiterated its Buy rating and $30 price target for ClearPoint following uniQure N.V. (NASDAQ:QURE) regulatory update on AMT-130, an experimental gene therapy for Huntington’s disease.

A team of scientists in lab coats studying a microscope, working on developing gene therapy solutions.

uniQure N.V. (NASDAQ:QURE) declared that it has partnered with the FDA to seek an expedited approval process for AMT-130. If the trials go well and the FDA approves it, Lake Street sees AMT-130 as maybe ClearPoint’s first “meaningful partner asset.”

ClearPoint provides disposables valued at almost $20,000 for each AMT-130 infusion, suggesting a significant financial benefit associated with the therapy’s effectiveness. The FDA’s support might result in the approval by the end of 2026, which would have a big effect on ClearPoint’s financial standing and confirm its strategic focus on image-guided neurosurgery and gene therapy delivery.

According to Lake Street, this regulatory milestone increases clarity on ClearPoint’s contribution to the advancement of clinical-stage gene treatments and provides further assurance regarding the clearance timeline for AMT-130.

While we acknowledge the potential of QURE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None.